Biogen Inc vs McDonald's Corp — how do they compare? Biogen Inc trades at $202.7 (market cap $30.13B), while McDonald's Corp trades at $273.83 (market cap $194.00B). The key difference: McDonald's Corp is far larger — about 6.4× Biogen Inc's market cap, and McDonald's Corp pays a 2.71% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | MCD | |
|---|---|---|
Market Cap | $30.13B | $194.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $341.06 |
52-Week Low | $128.93 | $262.80 |
Enterprise Value | $37.20B | $247.77B |
Volume | — | 2,230,036 |
Dividend Yield | — | 2.71% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
McDonald's (MCD) trades at $274.15, down slightly by 0.12% on the day, with technical indicators showing a neutral overall signal. The company demonstrates strong fundamentals with consistent revenue growth, reaching $26.89 billion in 2025, and robust profitability with a 31.72% net income margin. Recent earnings have consistently beaten expectations, and the company has announced a new global growth strategy focused on automation and menu innovation to drive future performance.
The outlook for MCD is positive, supported by strong analyst consensus with a $322.45 price target implying significant upside. Key opportunities include the successful execution of its new growth plan and its defensive qualities in a challenging economy. Primary risks involve inflationary pressures on franchisee margins and intense competition in the quick-service restaurant sector.
Trailing returns across standard periods
Latest headlines on both assets
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →